Minimally-invasive stone removal in urinary calculi patients during pregnancy: clinical therapeutic effects and low complications.

PURPOSE: To study the clinical effect of minimally-invasive surgery to treat urinary calculi and the prevention of surgery-associated complications during pregnancy. METHODS: A retrospective analysis of the clinical data of 96 pregnant urinary calculi patients admitted to our hospital from April 2017 to April 2018 was conducted. The patients were randomly divided into a study group and a control group, with 48 patients in each group. The control group was given extracorporeal shock wave lithotripsy (ESEL), and the study group underwent minimally-invasive percutaneous nephrolithotomies (MPCNL). The clinical efficacy and the complications associated with the two treatments were compared. RESULTS: The two groups' BUN and SCr levels were significantly decreased after the treatment (P < 0.05), with more significant reductions in the study group than in the control group (P < 0.001). There were marked reductions in the IL-6 and ET-1 levels in the two groups of patients post-treatment (P < 0.001), with greater decreases in the study group than in the control group (P < 0.001). The post-treatment CA and GLU levels were significantly lower than their pre-treatment values (P < 0.001), with greater decreases in the study group than in the control group (P < 0.001). Moreover, the patients' pain scores in the study group at post-surgery days 1, 3, and 5 were significantly lower than the post-surgery pain scores in the control group (P < 0.001). There were no significant differences in the stone removal rates between the two groups (P > 0.05). The Incidence of postoperative complications in the study group was significantly lower than the incidence in the control group (P < 0.05). CONCLUSION: The use of MPCNL for patients with urinary calculi during pregnancy effectively improves renal function, decreases the inflammatory and stress responses, and lowers the postoperative pain. Therefore, this treatment merits clinical application.

Phage and phage lysins: New era of bio-preservatives and food safety agents.

There has been an increase in the search and application of new antimicrobial agents as alternatives to use of chemical preservatives and antibiotic-like compounds by the food industry. The massive use of antibiotic has created a reservoir of antibiotic-resistant bacteria that find their way from farm to humans. Thus, there exists an imperative need to explore new antibacterial options and bacteriophages perfectly fit into the class of safe and potent antimicrobials. Phage bio-control has come a long way owing to advances with use of phage cocktails, recombinant phages, and phage lysins; however, there still exists unmet challenges that restrict the number of phage-based products reaching the market. Hence, further studies are required to explore for more efficient phage-based bio-control strategies that can become an integral part of food safety protocols. This review thus aims to highlight the recent developments made in the application of phages and phage enzymes covering pre-harvest as well as post-harvest usage. It further focuses on the major issues in both phage and phage lysin research hindering their optimum use while detailing out the advances made by researchers lately in this direction for full exploitation of phages and phage lysins in the food sector.

Ultra-effective near-infrared Photothermal therapy for the prostate cancer Nursing care through novel intended and surface tailored photo-responsive Ga-Au@MPS nanovesicles.

Surface tailored GaAu loaded mesoporous silica nanoparticles are considered as an important nanomaterial for biomedical applications such as diagnosis and cancer treatment. In this study, we used GaAu loaded mesoporous silica nanoparticles (Ga-Au@mSiO2) for the photothermal treatment of two prostate cancer cell lines. We systematically examined the nanocomposite form by various spectroscopic (UV-Vis, TGA and DTA) and electroscopic techniques (TEM and SEM including the elemental mapping analysis). After careful evaluation of the nanocomposite form, we performed cancer cell growth inhibition properties of the prostate cancer cell lines (DU145 and LNCaP). Also, we performed the photothermal effects of these nanocomposites on cell proliferation and apoptosis using different biochemical staining and flow cytometry. Our in vitro investigational datas are established Ga-Au@mSiO2 effectively exhibited and also with Ga-Au@mSiO2 + NIR the photothermal conversion therapy improved prostate cancer cells abolishing the prostate cancer cells. Interestingly, Ga-Au@mSiO2 + NIR was found to surpass the activity of Ga-Au@mSiO2 in all the cancer cells tested a topnotches. Hence, our current results demonstrated that surface tailored GaAu loaded mesoporous silica nanoparticles significantly inhibited the growth of prostate cancer cell lines and shown prominent antitumor effect in vitro. Thus, our study suggests that Ga-Au@mSiO2 + NIR could be used as impending anticancer candidate for photothermal ablation of prostate cancer cells. Further examinations of the mechanism indicated that anticancer activity was accomplished by inducing apoptosis in cancer cells, which is suggesting that these Ga-Au@mSiO2 + NIR nanocomposite can be used as promising candidates for nursing care cancer therapy.

Clusterin promotes growth and invasion of clear cell renal carcinoma cell by upregulation of S100A4 expression.

BACKGROUND AND OBJECTIVE: Clusterin promotes cell proliferation, motility and invasiveness in human renal cell carcinoma (RCC) cells but the underlying molecular mechanisms of this action are largely unknown. The aim of this study was to investigate the effects of clusterin on cancer cell growth, invasion and S100A4 expression and to determine the effects of clusterin on in vitro cell proliferation and migration and in vivo tumour growth in RCC cells. METHODS: We have established stable transfectants of highly invasive Caki-1 human RCC cells with expression of clusterin shRNA targeting clusterin (Caki-1/clusterin shRNA). We also established stable transfectants of 786-O human RCC cells with expression of clusterin cDNA plaismid (786-O/clusterin cDNA). Clusterin and S100A4 expression was detected by reverse transcription (RT) PCR and western blot assay; Caki-1/clusterin shRNA and 786-O/clusterin cDNA clones were subjected to in vitro-invasion assays. Cell viability and cell growth was assessed in MTT and clonogenic assay. Specific small interfering RNA was employed to down-regulate S100A4. The expression plasmid for S100A4 (pCMV-S100A4) was used to upregulate S100A4. Caki-1/clusterin shRNA clones were injected subcutaneously in nude mice to determine tumour growth and cancer cell invasiveness in vivo. Xenograft tumour tissues were assessed by immunohistochemistry and frozen tissues were used for the detection of S100A4 and clusterin. RESULTS: Overexpression of clusterin increased cell invasiveness; and targeting clusterin reduced cell invasiveness in vitro. This increase in cell invasiveness was mediated by S100A4. Targeting clusterin decreased cell proliferation and down-regulated cellular S100A4 levels in Caki-1 cells; Overexpression of clusterin increased cell proliferation and up-regulated cellular S100A4 levels in 786-O cells; Stable Caki-1/clusterin shRNA transfectants produced smaller xenograft tumours containing reduced S100A4 protein levels in vivo. Stable 786-O/clusterin cDNA transfectants produced larger xenograft tumours containing increased S100A4 protein levels in vivo. CONCLUSION: Our results indicate that clusterin promotes growth and invasion in RCC cells in vitro and in vivo through upregulation of S100A4; And targeting clusterin confers growth inhibitory and anti-invasive properties in RCC cells in vitro and in vivo through a down-regulation of S100A4. These findings provide the rationale for future oncostatic strategies aimed at suppressing clusterin-mediated signal transduction pathways as a novel therapeutic approach in human RCC.

Effects of jingyuankang capsules on leukocyte level in AIDS patients.

OBJECTIVE: To observe the therapeutic effects of Jingyuankang capsules for leukopenia in AIDS patients. METHODS: In this randomized double-blind trial, 58 patients orally took Jingyuankang capsule, analog Leucogen tablet and the HAART (highly active anti-retroviral therapy) drugs, and the other 58 patients took Leucogen tablet, analog Jingyuankang capsule and the HAART drugs all for 6 months, during which the peripheral hemogram was periodically examined to observe the therapeutic effects of Jingyuankang capsule for leukopenia of the AIDS patients. RESULTS: With good therapeutic effect for leukopenia of the AIDS patients, Jingyuankang capsule can enhance leukocyte level as effective as Leucogen tablet in treating grade I and grade II leukopenia, and more effectively than Leucogen tablet in treating grade III leukopenia. No toxic side-effects and adverse reactions were found during the treatment and in the follow-up visit. CONCLUSION: Jingyuankang capsule can effectively treat leukopenia of the AIDS patients.

Tumor necrosis factor--alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases.

BACKGROUND: Nonalcoholic Fatty Liver Disease (NAFLD) encompasses a histopathological spectrum of clinical conditions such as simple fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and a variant that has degrees of fibrosis. Tumor Necrosis Factor-alpha (TNF-alphalpha) is considered essential for NAFLD. Therefore, we investigated the correlation between TNF-alphalpha gene promoter polymorphism and NAFLD in this human study. PATIENTS AND METHODS: The TNF-alpha gene polymorphisms at position -238 and -308 were analyzed in 189 Chinese patients with NAFLD and 138 healthy controls by using polymerase chain reaction and restriction fragment length polymorphism assay. The serum levels of TNF-alpha in both patient and control groups were measured by ELISA. The associations of TNF-alpha polymorphism and serum TNF-alpha, and/or insulin resistance, and/or clinical features were analyzed. RESULTS: The carrier frequencies of TNF-alpha gene polymorphism with G/A mutation at -238 were significantly higher in the patients with NAFLD than those in the control subjects (p < 0.05). However, there were no significant differences between the NAFLD patients and control subjects in the polymorphisms at -308 (p > 0.05). In addition, the serum level of TNF-alpha was markedly higher in the patients with NAFLD than in the control subjects (p < 0.05). There were significant associations between TNF-alpha gene polymorphism in the -238 A allele and increased serum TNF-alpha, insulin resistance, as well as increased body mass index in the NAFLD patients. CONCLUSIONS: The results indicate that the TNF-alpha gene polymorphism at position -238 is associated with susceptibility of nonalcoholic Fatty Liver Disease in a Chinese population.